Chemical Effects
At the core of radiotherapy sensitization lies decreasing mitotic fraction of tumor cells, thus increasing radiation-induced cell cycle checkpoint inhibition or DNA damage response activation and thus more tumor cell deaths as a result of radiation-induced cell cycle checkpoint inhibition or DNA damage response activation. Numerous strategies have been explored in order to do this such as inhibiting certain DNA repair pathways such as ATM, ATR or DNA-PKcs as well as interfering with cell cycle regulating kinases; restoring cell death pathways like Apoptosis or modulating tumor microenvironments (like hypoxia or aberrant angiogenesis).
RF EMFs may directly target electrically charged subcellular structures like microtubules and their ionic flows. Studies in vitro have demonstrated that devices using LEAM RF EMF can interact resonantly with subcellular structures like this by producing carrier waves at frequencies close to therapeutic LEAM EMF envelope wave frequencies – specifically, disrupting microtubule ionic flow may lead to changes in cellular behavior that could have clinical relevance.
These changes may be driven by LEAM RF EMFs’ resonance with intracellular ion flows around mitochondria and nuclei, disrupting cell division and subcellular trafficking processes and leading to cell death. This may account for significant decreases in Warburg effect as well as shifts away from glycolysis seen both in vitro and mouse xenograft models exposed to specific LEAM RF EMF envelope wave frequencies.
Resonant interactions of RF EMFs with intracellular ion flows could account for the cytoprotective properties of radiation therapy in normal tissues, possibly related to its short exposure times for normal tissues that is much shorter than required for tumor cell repopulation or interfractional repair of sublethal damage.
At present, chemotherapy and radiation therapy (RT) combination treatments have proven highly successful for treating many malignancies. Combination therapy may be delivered sequentially or concurrently – for example with each modality given at its own scheduled interval – such as every 3-4 weeks. Another approach would involve administering “pulsed” treatments such as every three or four weeks.
